lamotrigine has been researched along with Obesity in 11 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the efficacy and safety of lamotrigine in binge-eating disorder (BED) associated with obesity." | 9.14 | Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. ( Guerdjikova, AI; Hudson, JI; Keck, PE; McElroy, SL; Nelson, E; Welge, JA, 2009) |
| "The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium)." | 9.12 | Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. ( Bentley, B; Bowden, C; Calabrese, JR; Ketter, T; Sachs, G; Thompson, T; White, R, 2006) |
| "Unlike many pharmacotherapies for mood disorders, lamotrigine has not been shown to be associated with weight gain." | 9.12 | A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults. ( Merideth, CH, 2006) |
| "Aripiprazole plus a mood stabilizer has minimal impact on metabolic changes in predominantly overweight/obese BPD patients over a 52-week period." | 5.17 | Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine. ( Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z, 2013) |
| "This study evaluated the efficacy and safety of lamotrigine in binge-eating disorder (BED) associated with obesity." | 5.14 | Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. ( Guerdjikova, AI; Hudson, JI; Keck, PE; McElroy, SL; Nelson, E; Welge, JA, 2009) |
| "The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium)." | 5.12 | Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. ( Bentley, B; Bowden, C; Calabrese, JR; Ketter, T; Sachs, G; Thompson, T; White, R, 2006) |
| "Unlike many pharmacotherapies for mood disorders, lamotrigine has not been shown to be associated with weight gain." | 5.12 | A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults. ( Merideth, CH, 2006) |
| "A post hoc analysis was conducted to assess the effects of lamotrigine, lithium, and placebo administration on body weight in obese and nonobese patients with bipolar disorder from two double-blind, placebo-controlled, 18-month studies." | 5.12 | Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. ( Bowden, CL; Calabrese, JR; Ketter, TA; Sachs, GS; Thompson, TR; White, RL, 2006) |
| "Metabolic syndrome was more frequently associated with VPA-treated patients (41." | 1.34 | Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. ( Kim, JY; Lee, HW, 2007) |
| "Psychopharmacology research aims to expand the therapeutic ratio between efficacy, on the one hand, and adverse events and safety, on the other." | 1.31 | Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. ( McIntyre, RS, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guerdjikova, AI | 1 |
| McElroy, SL | 1 |
| Welge, JA | 1 |
| Nelson, E | 1 |
| Keck, PE | 1 |
| Hudson, JI | 1 |
| Kemp, DE | 1 |
| De Hert, M | 1 |
| Rahman, Z | 1 |
| Fyans, P | 1 |
| Eudicone, JM | 1 |
| Marler, SV | 1 |
| Baker, RA | 1 |
| Carlson, BX | 1 |
| Biton, V | 1 |
| Levisohn, P | 1 |
| Hoyler, S | 1 |
| Vuong, A | 1 |
| Hammer, AE | 1 |
| Sachs, G | 1 |
| Bowden, C | 1 |
| Calabrese, JR | 2 |
| Ketter, T | 1 |
| Thompson, T | 1 |
| White, R | 1 |
| Bentley, B | 1 |
| Merideth, CH | 1 |
| Bowden, CL | 1 |
| Ketter, TA | 1 |
| Sachs, GS | 1 |
| White, RL | 1 |
| Thompson, TR | 1 |
| Bigham, S | 1 |
| McGuigan, C | 1 |
| MacDonald, BK | 1 |
| Kim, JY | 1 |
| Lee, HW | 1 |
| Stephen, LJ | 1 |
| Kwan, P | 1 |
| Shapiro, D | 1 |
| Dominiczak, M | 1 |
| Brodie, MJ | 1 |
| McIntyre, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity: A Single-Center, Double-Blind, Placebo-Controlled, Flexible-Dose Study in Outpatients[NCT00277641] | Phase 3 | 70 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
6 trials available for lamotrigine and Obesity
| Article | Year |
|---|---|
Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Body Mass Index; Bulimia Nervosa; Double-Blind Method; Fe | 2009 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug | 2013 |
Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Body Mass Index; Child; Double-Blind Metho | 2003 |
Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Body Weight; Double-Blind Method; Female; Humans; Inc | 2006 |
A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults.
Topics: Adult; Anticonvulsants; Body Mass Index; Double-Blind Method; Drug Administration Schedule; Female; | 2006 |
Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Body Weight; Comorbidity; Double-Blind Method; Humans; Lam | 2006 |
5 other studies available for lamotrigine and Obesity
| Article | Year |
|---|---|
Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat.
Topics: Adolescent; Anti-Obesity Agents; Anticonvulsants; Drug Interactions; Drug Monitoring; Epilepsy; Fema | 2006 |
Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Carbamazepine; Comorbidity; Epil | 2007 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy.
Topics: Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Comorbidity; Dehydroepiandrosterone; Epileps | 2001 |
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.
Topics: Anticonvulsants; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Female; Fructose; Humans; La | 2002 |